JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.
FDA approves Taiho’s Lonsurf with bevacizumab for metastatic colorectal cancer
The FDA on Wednesday approved Taiho Oncology’s Lonsurf (trifluridine and tipiracil) with bevacizumab for metastatic colorectal cancer (mCRC) in those who were previously treated with